#2112 Cycloheximide

Western Blotting

Western blot analysis of extracts from Jurkat cells, untreated (-) , or treated with Cycloheximide (50 μg/ml, 24 hr; +), Bortezomib #2204 (10 nM, 24 hr; +), or both, using Ubiquitin Antibody #3933 (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower).

Western Blotting

Western blot analysis of extracts from Jurkat cells, untreated (-) or treated with increasing concentrations of Cycloheximide (24 hr), using PARP Antibody #9542 (upper), Cleaved PARP (Asp214) (D64E10) XP^® Rabbit mAb #5625 (middle), or β-Actin (D6A8) Rabbit mAb #8457 (lower).

Structure

Chemical structure of cycloheximide.

Cycloheximide is a protein synthesis inhibitor in eukaryotes. Although its precise mechanism of action has yet to be fully elucidated, it has been shown to inhibit translation elongation through binding to the E-site of the 60S ribosomal unit and interfering with deacetylated tRNA (1-3). Although not all cell types are equally sensitive to the apoptosis-inducing effects of cycloheximide, it has been shown to induce cell death in T cells through a FADD-dependent mechanism (4). In addition, cycloheximide and Tumor Necrosis Factor possess a synergistic cytotoxicity (5,6), and consequently they are routinely used together to induce cell death. Investigators have demonstrated that cycloheximide blocks bortezomib-stimulated protein ubiquitination (7).

1. Schneider-Poetsch, T. et al. (2010) Nat Chem Biol 6, 209-217.
2. Klinge, S. et al. (2011) Science 334, 941-8.
3. Pestova, T.V. and Hellen, C.U. (2003) Genes Dev 17, 181-6.
4. Tang, D. et al. (1999) J Biol Chem 274, 7245-52.
5. Nolop, K.B. and Ryan, U.S. (1990) Am J Physiol 259, L123-9.
6. Reid, T.R. et al. (1989) J Biol Chem 264, 4583-9.
7. Mimnaugh, E.G. et al. (2004) Mol Cancer Ther 3, 551-66.